Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Nov 17;12:6655. doi: 10.1038/s41467-021-26821-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 7 — a OS of patients with higher (above median, blue) tumor mutational burden (TMB) versus patients with lower (below median, red) TMB. b OS of patients with higher (above median, blue) copy number aberration (CNA) burden versus patients with lower (below median, red) CNA burden. c OS of patients with more homogeneous T-cell receptor (TCR) repertoire (higher above-median TCR Jaccard index (JI), blue) versus patients with more heterogeneous TCR repertoire (lower below-median TCR JI, red). d OS of patients with tumors of higher (above median, blue) tumor purity versus patients with tumors of lower (below median, red) tumor purity. e OS of patients with tumors of higher (no less than median, blue) CD3 + tumor-infiltrating lymphocytes (TILs) versus patients with tumors of lower (below median, red) CD3 + TILs. f OS of patients with tumors of positive (above 0, blue) programmed death ligand-1 (PD-L1) expression versus patients with tumors of negative (equal to 0, red) PD-L1 expression. Two-sided log-rank test was used for survival analysis. Source data are provided as a Source Data file.